References
Klein S, Burke LE, Bray GA, et al.: Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation 2004, 110:2952–2967.
Bays HE: Current and investigational antiobesity agents and obesity therapeutic treatment targets. Obes Res 2004, 12:1197–1211.
Cota D, Marsicano G, Tschop M, et al.: The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003, 112:423–431.
Black SC: Cannabinoid receptor antagonists and obesity. Curr Opin Investig Drugs 2004, 5:389–394.
Rights and permissions
About this article
Cite this article
Houri, M., Pratley, R.E. Rimonabant: A novel treatment for obesity and the metabolic syndrome. Curr Diab Rep 5, 43–44 (2005). https://doi.org/10.1007/s11892-005-0066-4
Issue Date:
DOI: https://doi.org/10.1007/s11892-005-0066-4